Morphological evaluation of brain oligodendroastrocytomas sensitivity to antiblastic radiation therapy and chemotherapy


  • Volodymyr Rozumenko Department of Intracerebral Tumors, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Vera Semenova Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Valentyn Klyuchka Department of Intracerebral Tumors, Romodanov Neurosurgery Institute, Kiev, Ukraine



oligoastrocytoma, histological features, antiblastic therapy


Introduction. The results of oligoastrocytomas (OA) comparative morphological analysis before and after antiblastic therapy are given. Histological changes of OA were identified at extended growth after treatment.

Materials and methods. Morphological features of 34 brain OA, removed during first and repeated operation, after different types of antiblastic therapy, were studied.

Results. It was found out that according to treatment pathomorphosis features most (76.5%) OA were sensitive to adjuvant therapy that manifested in the form of cytodestructive or cytotoxic reaction.

Conclusions. Histological heterogeneity of OA, different relationships of their components and different degrees of anaplasia cause different responses of these tumors to postoperative radiotherapy, chemotherapy or chemoradiotherapy.

Author Biography

Vera Semenova, Romodanov Neurosurgery Institute, Kiev

Tissue Culture Laboratory


1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Fourth Edition. Lyon, France: IARC Press; 2007. 312 p.

2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97-109. [PubMed] [CrossRef]

3. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006 Jun 20;24(18):2715-22. [PubMed] [CrossRef]

4. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol. 2009 Apr;11(2):167-75. [PubMed] [CrossRef]

5. Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, du Plessis DG, Warnke PC. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology. 2006 Jun 13;66(11):1661-7. [PubMed] [CrossRef]

6. Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002 Sep;64(3):259-73. Review. [PubMed] [CrossRef]

7. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun;13(6):649-59. [PubMed] [CrossRef]

8. Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels JF, Bourg V, Paquis P, Chatel M, Frenay M; Nice Brain Tumor Study Group. Long-term outcome of oligodendrogliomas. Neurology. 2004 May 25;62(10):1783-7. [PubMed] [CrossRef]

9. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001 Nov;95(5):735-45. Review. [PubMed] [CrossRef]

10. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000 Feb;18(3):636-45. [PubMed]

11. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006 Jun 20;24(18):2707-14. [PubMed] [CrossRef]

12. Klyuchka VM. Diahnostyka ta khirurhichne likuvannya olyhoastrotsytoma pivkul velykoho mozku [Diagnosis and surgical treatment of cerebral hemispheres olyhoastrotsytoma] [dissertation]. Kiev (Ukraine): Romodanov Neurosurgery Institute; 2009. Ukrainian.

13. Vinogradov VM, Kartashev AV. Khimioluchevaya terapiya opukholey golovnogo mozga [Chemoradiation therapy of brain tumors]. Prakticheskaya onkologiya. 2008;9(1):47–56. Russian. []

14. Galanin KA, Yugrinov YuG, Kurik YeG, Melnik NN, Koshubarova MV, Polyakova TV, Bazdyrev V. Khimio Terapevticheskiy patomorfoz zlokachestvennykh opukholey. Ukrainskiy khimioterapevtichniy zhurnal. 2000;4(8):8-12. Ukrainian.

15. Kropaneva VV. Otsenka effektivnosti ispolzovaniya lekarstvennoy terapii v kombinirovannom lechenii bolnykh rakom sheyki matki Ib2 – III stadiy [Evaluating the effectiveness of drug therapy in the combined treatment of patients with cervical cancer Ib2 - III stages] [dissertation]. St.Petersburg (Russia): Petrov Research Institute of Oncology; 2004. Russian.

16. Kobyakov GL. Khimioterapiya v lechenii zlokachestvennykh vnutrimozgovykh opukholey [Chemotherapy in the treatment of malignant intracerebral tumors]. Sovremennaya onkologiya. 2002;(1):43–45. Russian.

17. Lushnikov YeF. Lechebnyy patomorfoz opukholey [Medical pathomorphosis in tumors]. In: Kraevskiy NA, Smolyannikov AV, Sarkisov DS, editors. Patologoanatomicheskaya diagnostika opukholey cheloveka [Pathologic diagnosis of human tumors]. Moscow: Meditsyna; 1993. 560 p. Russian.

18. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4. Review. [PubMed] [CrossRef]



How to Cite

Rozumenko, V., Semenova, V., & Klyuchka, V. (2013). Morphological evaluation of brain oligodendroastrocytomas sensitivity to antiblastic radiation therapy and chemotherapy. Ukrainian Neurosurgical Journal, (2), 13–18.



Original articles